Cubismi's transformational AI-powered Decision Technology platform is designed to allow physician users to easily pull insights from oceans of big data to make better patient care decisions, quickly, in fast paced clinical environments. It is the first and only AI-powered Decision Technology to connect intelligence and analytics insights into a synthesized decision-making framework for clinical teams.
Cubismi’s Decision Flow™-3D foundational AI-powered cloud technology leverages a cutting-edge “data mesh” informatics technology to anatomically structure data from a potentially unlimited array including medical imaging, genomics and proteomics into holistic AI-enabled 3D-time interactive virtual maps for each patient. Combined with machine learning and AI algorithms, the system is designed for a leap for forward in ergonomic human-information interaction. Machine learning predictions from this structured data design allows for three major leaps forward. First, it will allow a new intuitive order to allow physicians to triage “signal from noise” during decision-making. Second, multi-modal data integrations will provide critically-needed granular biomarkers for cancer and other diseases. Last, this ground-breaking design will, for the first time, allow holistic integration of patient care outcomes metrics and “connected intelligence” across multiple physician decision-makers. This design will allow faster insights and improved recommended actions, and will enable future continuous monitoring and improvement of patient care outcomes.
Cubismi's patent-protected "Hypercube" technology leverages the structured 3D-Time Patient Virtual Maps to stitch diverse types of health data, combined with a "moving windows" (akin to CNN sliding windows) which classifies stitch data in comparison to population data. "Moving windows" can use "AI" neural networks. The results in granular precision predictions, which are critical need for cancer. Cubismi's specific method, and similar methods, have been validation been validation by numerous publications in leading journals. Cubismi's platform will further enable this research and specific use cases for cancer and other diseases.